Inclusion criteria | ||
General step 1 | ||
1 Patients > 18 years at time of inclusion capable of giving signed informed consent. | ||
2 Performance status ECOG of 0 or 1. | ||
3 Life expectancy ≥6 months. | ||
4 Body weight > 30 kg. | ||
5 Patients diagnosed with a solid malignancy, histologically confirmed (see cohort specific inclusion criteria below). | ||
6 Presence of mutation in homologous repair gene (BRCA1, BRCA2, PALB2, ATM, FANCA, FANCB, FANCC, FANCE, FANCF, CHEK2, RAD51, BARD1, MRE11, RAD50, NBS1, HDAC2), LKB1/STK11, INPP4B, STAG2, ERG, CHEK1, BLM, LIG4, ATR, ATRX, CDK12). Homozygote or heterozygote mutations and loss of heterozygosity of the second allele accepteda. | ||
7 At least one lesion measurable as defined by standard imaging criteria for the patient’s tumor type (RECIST v1.1) that can be accurately assessed at baseline and suitable for repeated assessment. | ||
8 Patients must have normal organ and bone marrow function. | ||
9 Female and male with adequate contraception method. | ||
10 For all oral medications patients must be able to comfortably swallow capsules. | ||
11 Patients affiliated to a social security regimen or beneficiary of the same according to local requirements. | ||
General step 2 | ||
12 CT Scan evaluation after 6 weeks of olaparib should present response or stable disease as defined by RECIST v1.1 criteria. | ||
Inclusion criteria | ||
Cohort specific | ||
Breast cancerbd - 2nd line and after | Lung cancerbd - Non-small cell lung cancer. - Must have progressed after at least a first line with platinum based therapy. | Head and neck cancerbd - Must have progressed after at least a 1st line with platinum based therapy. |
Metastatic endometrial cancerbd - Progression after one prior systemic, platinum-based chemotherapy. | Clear cell renal cancerbd - Must have progressed after at least a line with anti-angiogenic agent. | Pancreatic cancerbd - Must have progressed after at least a line with FOLFIRINOX regimen and/or Gemcitabine based chemotherapy. |
Ovarian cancerce - Must have received at least one and no more than two lines of prior platinum-containing therapy and progressed after the most recent platinum therapy in a platinum-sensitive timeframe (more than 6 months from the last dose of platinum before randomization). | Urothelial cancerbd - -2nd line and after. | Prostate cancerbd - Documented evidence of metastatic castration resistant prostate cancer (mCRPC). - Ongoing therapy with LHRH analog or bilateral orchiectomy. Must have progressed on prior new hormonal agent (enzalutamine or abiraterone) and taxane chemotherapy. |